AllSci News
Orca Bio’s Tregzi gets FDA nod as first allogeneic regulatory T cell therapy for transplant patients
The US FDA approved Tregzi (HSPC and T cells-vldq), developed by Orca Bio, for use in matched donor hematopoietic stem cell transplantation…
Will Therapeutics pursues first targeted drug for anorexia nervosa’s compulsive neural circuits
Montreal-based Will Therapeutics announced a government-backed research collaboration with the Douglas Hospital Research Centre to develop brain-penetrant small molecules targeting the neural…
Xellar closes USD 50m Series A to build AI-powered organ-on-chip drug discovery platform
Boston-based Xellar Biosystems has closed a USD 50 million Series A and A+ financing round to advance its organ-on-chip-based drug discovery platform, which...
METiS scores up to USD 1.62b from Deerfield's Boulevard Bio for preclinical trispecific TCE
Hong Kong-listed METiS TechBio (HKEX: 7666) has licensed its preclinical trispecific T-cell engager MTS-128 to Boulevard Bio, a Deerfield Management-backed...
FDA grants Kowa’s pemafibrate breakthrough therapy designation for PBC
Japan-based Kowa Company, Ltd. announced on June 30 that the US FDA granted Breakthrough Therapy Designation (BTD) to K-808 (pemafibrate), a selective…
Washington Uni secures USD 16.5m to expand DIAN-TU anti-tau Alzheimer's platform
The Washington University neurology department in St. Louis has received a USD 16.5 million NIA R01 renewal to continue the Dominantly Inherited Alzheimer...
Hengrui’s Heng Yi wins China approval as second EyeSol-based dry eye therapy
China’s National Medical Products Administration (NMPA) has approved Heng Yi (cyclosporine ophthalmic solution 0.1%) for the treatment of dry eye disease, marking…
FDA launches PreCheck Pilot program to accelerate domestic drug manufacturing facility approvals
Category: Regulatory Policy | Regulatory Body: FDA | Geography: United States | Instrument: Initiative launch
Brukinsa becomes first BTK inhibitor to beat chemo in frontline MCL
BeOne Medicines (Nasdaq: ONC) reported positive topline results from the Phase III MANGROVE trial showing that zanubrutinib (Brukinsa) plus rituximab...
Moffitt wins USD 1.66 million NCI grant to target MYC-driven inflammation in myelofibrosis
Moffitt Cancer Center has received a USD 1.66 million National Cancer Institute R01 renewal to investigate a MYC-driven inflammatory pathway as a potential...
New York Genome Center aims to lower barriers to spatial multi-omics with NIH funding
New York Genome Center (NYGC) has received a USD 2.68 million NIH R01 grant from the National Human Genome Research Institute to develop a cost-accessible...
Washington Uni explores whether sleep aid suvorexant can slow Alzheimer's pathology
Washington University in St. Louis has received a USD 1.47 million National Institute on Aging R01 renewal to evaluate whether chronic treatment with the...
MSK backed by NCI to explore lethal hyperactivation of WNT, MAPK, and PI3K in colorectal cancer
Memorial Sloan-Kettering Cancer Center has received a USD 1.71 million NCI OT2 award to pursue a counterintuitive approach to colorectal cancer treatment:...
Lilly outsources Verzenios commercialization in China to Innovent, deepening eight-deal partnership
Eli Lilly hands Innovent sole commercialization rights to abemaciclib in mainland China, deepening an eight-deal partnership as Lilly systematically...
Sanofi's Nexviazyme clears path to replace Myozyme in infantile-onset Pompe disease
Sanofi (Nasdaq: SNY) reported that avalglucosidase alfa (Nexviazyme) met all primary and secondary endpoints in the Baby-COMET Phase III study in...
The AllSci Brief
Free, systematic R&D and deal news. Daily.